Taiwan’s Free Trade Agreements (FTAs) promote faster market access by harmonizing regulatory processes and facilitating drug imports. These agreements align intellectual property protections with international standards, benefiting innovative medicines. However, stricter patent rules under FTAs may delay the availability of generics, impacting affordability and competition in the pharmaceutical market